Breast Cancer Research (Jun 2024)

Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019

  • Jenna Bhimani,
  • Kelli O’Connell,
  • Isaac J. Ergas,
  • Marilyn Foley,
  • Grace B. Gallagher,
  • Jennifer J. Griggs,
  • Narre Heon,
  • Tatjana Kolevska,
  • Yuriy Kotsurovskyy,
  • Candyce H. Kroenke,
  • Cecile. A. Laurent,
  • Raymond Liu,
  • Kanichi G. Nakata,
  • Sonia Persaud,
  • Donna R. Rivera,
  • Janise M. Roh,
  • Sara Tabatabai,
  • Emily Valice,
  • Erin J.A. Bowles,
  • Elisa V. Bandera,
  • Lawrence H. Kushi,
  • Elizabeth D. Kantor

DOI
https://doi.org/10.1186/s13058-024-01822-9
Journal volume & issue
Vol. 26, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background Little is known about how use of chemotherapy has evolved in breast cancer patients. We therefore describe chemotherapy patterns for women with stage I-IIIA breast cancer in the Optimal Breast Cancer Chemotherapy Dosing (OBCD) Study using data from KPNC (Kaiser Permanente Northern California) and KPWA (Kaiser Permanente Washington). Findings Among 33,670 women, aged 18 + y, diagnosed with primary stage I-IIIA breast cancer at KPNC and KPWA from 2006 to 2019, we explored patterns of intravenous chemotherapy use, defined here as receipt of intravenous cytotoxic drugs and/or anti-HER2 therapies. We evaluated trends in chemotherapy receipt, duration over which chemotherapy was received, and number of associated infusion visits. In secondary analyses, we stratified by receipt of anti-HER2 therapies (trastuzumab and/or pertuzumab), given their longer duration. 38.9% received chemotherapy intravenously, declining from 40.2% in 2006 to 35.6% in 2019 (p-trend < 0.001). Among 13,089 women receiving chemotherapy, neoadjuvant treatment increased (4.1–14.7%; p-trend < 0.001), as did receipt of anti-HER2 therapies (20.8–30.9%) (p-trend < 0.001). The average treatment duration increased (5.3 to 6.0 months; p-trend < 0.001), as did the number of infusion visits (10.8 to 12.5; p-trend < 0.001). For those receiving anti-HER2 therapies, treatment duration and average number of visits decreased; among those not receiving anti-HER2 therapies, number of visits increased, with no change in duration. Conclusions While the prevalence of chemotherapy receipt has decreased over time, the use of neoadjuvant chemotherapy has increased, as has use of anti-HER2 therapies; duration and number of administration visits have also increased. Understanding these trends is useful to inform clinical and administrative planning.

Keywords